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A cDNA clone encoding a taurine transporter, designated HTAU, has been isolated from human thyroid. It contains an open reading frame 
encoding a protein of 619 amino acids with a calculated molecular weight of 69,675 Da. The predicted amino acid sequence of HTAU is highly 
homologous to those of dog kidney and rat brain. The HTAU mRNA was detectable in various human tissues examined. Transient expression 
of HTAU in COS-7 cells conferred a higher taurine uptake. The taurine uptake in FRTL-5 cells appears to be regulated by thyrotropin through 
CAMP. Finally, a higher taurine uptake may be associated with a higher proliferation rate in some cultured cell lines. 
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1. INTRODUCTION 
Taurine, 2-aminoethanesulfonic acid, is a major in- 
tracellular p-amino acid in mammals. It is most abun- 
dant in tissues that are excitable, are rich in membranes, 
and that generate oxidants [l]. Proposed functions of 
taurine include: membrane stabilization, detoxification, 
antioxidation, osmoregulation, modulation of calcium 
flux, and a role as a neurotransmitter or neuromodula- 
tor. It is well established that taurine is essential for 
retinal integrity and function [2]. Furthermore, taurine 
deficiency has been reported in several members of a 
family who had mild depression, insomnia, anorexia, 
dysphagia, dyspnea, and loss of visual depth perception 
[3]. Recently, taurine has been shown to have a pro- 
tective effect on myocardial alterations caused by 
prolonged treatment with norepinephrine in rats [4]. 
Significant reatment effect was observed on systolic left 
ventricular function in taurine-treated patients with 
congestive heart failure [5]. It is generally accepted that 
taurine has inhibitory neurotransmitter properties in 
the retina and central nervous system. Recently, it has 
been suggested that taurine may modulate neuroactivity 
by inhibiting the phosphorylation of specific proteins 
regulated by the signal transduction system in the brain 
[6]. To date, it is still unknown how a single molecule, 
taurine, possesses uch diversified function in various 
tissues of animals. Furthermore, little is known about 
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the molecular properties, regulation and expression of 
the taurine transporter. 
In an attempt to clone Na’-dependent transporters 
from the human thyroid gland, we have isolated a 
cDNA clone encoding the human taurine transporter. 
The primary structure of the human taurine transporter 
was determined, and compared with the recently cloned 
dog kidney [7] and rat brain taurine transporters [8]. 
Additionally, the distribution of taurine transporter in 
various human tissues was demonstrated. The regula- 
tion of taurine uptake in thyroid cells was investigated. 
Finally, taurine uptake was measured in several cul- 
tured cell lines. 
2. MATERIALS AND METHODS 
2.1. Cloning and sequencing 
A human thyroid cDNA library, cloned into the EcoRI site of the 
lambda gtl0 cloning vector, was obtained from Clontech laboratory 
(Palo Alto, CA). The cDNA library was screened with 32P-labeled 
DNA fragments, which include the DNA sequence ncoding the trans- 
membrane regions I to V of the GABA neurotransmitter [9]. The 
hybridized filters were washed at low stringency (2 x SSC, 0.1% SDS, 
SO’C). One of the positive clones containing an insert of approxi- 
mately 4 kb, designated HTAU, was further characterized and se- 
quenced using the USB sequenase kit. The DNA sequence was then 
subjected to a homology search using the BLAST network service 
provided by NCBI [lo]. 
2.2. Tissue distribution of HTAU 
Reverse transcription-polymerase chain reaction (RT-PCR) was 
performed to identify tissues expressing HTAU mRNA. Two oligom- 
ers derived from amino acids 8692 and 309-3 15 of HTAU were used 
for the PCR reaction. Therefore, a target fragment of 687 bp was 
expected. The PCR products were separated by gel electrophoresis 
and blotted to nylon membrane. The ‘*P-labelled DNA fragments of 
HTAU were used as probes to confirm the HTAU-specific PCR prod- 
ucts. 
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2.3. Functional expression of HTA U in COS-7 cells 
FEBSLETTERS 
The HTAU cDNA was subcloned into the eukaryotic expression 
vector pSG5 (Stratagene). The orientation of the cDNA was deter- 
mined by restriction analysis. The HTAU was introduced into COS-7 
cells, a monkey kidney cell line (ATCC CRL 1651), by Lipofectin 
(BRL). Taurine or iodide uptake in these transiently transfected cells 
was measured 2 days after the transfection. For the taurine uptake 
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assay, cells were incubated with 70 nM [1,2-‘Hltaurine (28 Ci/mmol) 
in fresh medium for 1 h at room temperature, followed by washing 3 
times with ice-cold Hanks Balanced Salt Solution (HBSS). The cells 
were then solubilixed with 1% SDS for [3H]taurine counting by liquid 
scintillation. For the iodide uptake assay [1 11, cells were incubated in 
500 ~1 of fresh medium containing 1 PCi of Na’*‘I and 5 PM NaI for 
40 min at 37°C. Cells were then washed once with HBSS, and incu- 
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Fig. 1. Alignment of the human, dog, and rat taurine transporters. The 12 putative transmembrane domains (I-XII) are underlined. (.) indicates 
identical amino acids. The potential N-linked glycosylation sites (*), protein kinase C phosphorylation sites (w), and casein kinase II phosphorylation 
sites (a) are indicated. 
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bated in 500 ~1 of 95% ethanol for 20 min at room temperature. The 
ethanol was then collected and the ‘25I content was measured by 
gamma-counting. Both taurine- and iodide-uptake activities were ex- 
pressed as cpm x 1,000/105 cells. 
2.4. TSH regulation of taurine uptake in FRTL-5 cells 
FRTL-5 cells, established from normal rat thyroid cells (ATCC 
CRL 8305), conserve most of the physiological characteristics of the 
thyroid, such as thyrotropin (TSH)dependent iodide uptake and 
growth. These cells were normally maintained in Coon’s F12 medium 
containing six hormones and 5% fetal calf serum (FCS) [12]. In this 
study, FRTL-5 cells were deprived of TSH for 8 days, followed by 
8-bromo-cAMP, or TSH treatment for 3 days before taurine- or io- 
dide-uptake assay was performed. 
2.5. Proliferation rate of human thyroid carcinoma derived cell lines 
TPC-1 and NPA are cells derived from human papillary thyroid 
carcinomas. TT (ATCC CRL 1803) and WRO cells were established 
from human medullary thyroid carcinoma, and follicular thyroid car- 
cinoma, respectively. TPC-1 cells were maintained in DMEM high 
glucose medium containing 5% FCS. NPA, WRO, and TT cells were 
maintained in RPMI-1640 medium containing 10% FCS. To deter- 
mine the proliferation rate of these cells, 5 x 104 cells per well were 
plated on 24well plate, and cells were harvested for cell number 
counting after 21, 46.5 and 69.5 h incubation. Taurine uptake was 
measured after cells were plated for 21 h. 
2.6. Statistical analyses 
ANOVA was used to compare the results among three or more 
groups with Newman-Keuls test for multiple comparison. A P-value 
equal or less than 0.05 was considered significant. 
3. RESULTS AND DISCUSSION 
3.1. The primary structure of HTA U 
The 3,957~nucleotide cDNA contains an open read- 
ing frame composed of nucleotides 141,873. This open 
reading frame encodes a protein of 6 19 amino acids with 
Muscle 
0-v 
Placenta 
Spleen 
Thyroid 
W 
a calculated molecular weight of 69,675 Da. The amino 
acid sequence ncoded by HTAU (Fig. 1) shows 91% 
identity with the dog kidney taurine transporter [7], and 
93% identity with the rat brain taurine transporter [8]. 
Most of the non-homologous residues are located in the 
second extracellular loop and the C-terminal regions. 
The putative 12 transmembrane segments were pre- 
served in HTAU, and the hydropathy plots of these 3 
taurine transporters are almost identical. Three poten- 
tial N-glycosylation sites, located in the second extracel- 
lular loop, are conserved in the taurine transporters 
from human, dog and rat. However, an additional po- 
tential N-glycosylation site in the last extracellular loop 
was found only in HTAU, suggesting that this site may 
not be important for the role of tam-me uptake. Accord- 
ing to the predicted amino acid sequence, the taurine 
transporter may be a phosphoprotein. Six potential pro- 
tein kinase C phosphorylation sites and seven potential 
casein kinase II phosphorylation sites were found in the 
HTAU protein (Fig. 1). It is noteworthy that protein 
kinase C activation has been reported to play an impor- 
tant role in the regulation of taurine uptake in cultured 
renal epithelial cells [ 131. Therefore, protein phospho- 
rylation may play an important role in the regulation of 
the activity of HTAU. 
A search of the GenBank showed about 60% amino 
acid identity, and about 80% amino acid similarity with 
the dog betaine transporter [141 in the region of residues 
27-581. Furthermore, there is 63% identity, and 81% 
similarity with the rat choline transporter [15] in the 
residues 193-508. Finally, there is 40-56% identity, and 
61-75% similarity with the neurotransmitter trans- 
porters [16] in various regions of residues 34-557. 
Breast 
Colon 
Heart 
Kidney 
Liver 
t-40 
Fig. 2. Tissue distribution of HTAU mRNA as determined by RT-PCR. Three pg of total RNA isolated from each tissue was used for cDNA 
synthesis in a total of 20 ~1 reaction volume. However, the RNA isolated from placenta was significantly degraded. One ~1 of the cDNA reaction 
mixture was used for PCR amplification (94OC, 30 s, 60°C, 1 min. 72°C 2 min for 40 cycles), and one third of the PCR product was used for 
gel electrophoresis. The amplified HTAU products were detected by hybridization with ‘*P-labelled DNA probes derived from HTAU. An 
autoradiogram of the Southern blot is shown. 
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cpm x lOOO/ 100,000 cells 
vector only 0.1 ug 0.5 ug 
Fig. 3. Transient expression of HTAU in COS-7 cells conferred a higher taurine uptake. Taurine uptake was measured in COS-7 cells, which were 
transfected with 0.5 pg pSG5 vector, or 0. I pg. 0.5 pg of the pSG5 carrying the HTAU cDNA. Each bar represents the mean 2 standard deviation 
of triplicates from a single experiment that was repeated with similar results. There is signific~t difference between vector and HTAU transfected 
COS-7 cells (P = 0.006). However, no signiticant difference was found between 0.1 ,!fg and 0.5 fig HTAU transfected COS-7 cells. 
3.2. Tissue distri~~t~an of HTA U 
As shown in Fig. 2, the HTAU mRNA was detected 
in all of the human tissues examined, including breast, 
colon, heart, kidney, liver, muscle, ovary, placenta, 
spleen, and thyroid. However, the HTAU mRNA rep- 
resents a rare transcript in all of the tissues examined 
by Northern analysis, including colon, liver, ovary, 
spleen and thyroid (data not shown). Recently, it has 
been shown that protein synthesis and protein kinase C 
activation, but not RNA transcription, appear to be 
important for the regulation of taurine uptake in cul- 
tured renal epithelial cells [13]. 
3.3. Transient expression of HTAU in COS-7 cells con- 
fers a higher taurine uptake 
The COS-7 cells transiently transfected with pSG5 
cpm x 1000/100,000 cells 
12 
10 
8 
6 
II -TSH q CAMP +TSH 
Fig. 4. The taurine uptake in FRTL-5 cells is TSH-dependent, and the TSH-stimulated taurine uptake could be mimicked by exogenous CAMP. 
For comparison, the iodide uptake was determined in parallel wells. Each bar represents the mean + standard deviation of triplicates from a single 
experiment that was repeated with similar results. There is significant difference in iodide uptake among TSH deprived, CAMP treated, and TSH 
revived FRTL-5 cells (P c 0.001). However, in the case of taurine uptake, while the difference between TSH deprived cells and both CAMP and 
TSH treated cells is significant (P c O.OOl), the CAMP and TSH treated groups showed no significant difference. 
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Fig. 5. (A) Correlation between taurine uptake and proliferation rate in TPC-1, COS-7, NPA, WRO and TT cells. R, regression coefficient. The 
uptake assay and cell number counting were performed 21 h after cells were plated at 5 x 104 cells per well. (B) The taurine uptake measured in 
TPC-I, TT, and WRO cells that were plated in three different cell densities. Each bar represents the mean f standard deviation of triplicates from 
a single experiment hat was repeated with similar results. 
carrying HTAU cDNA accumulated 4-5fold more 
t3H]taurine than did control cells (Fig. 3). The control 
cells include mock transfected, pSG5 vector transfected, 
and pSG5 carrying antisense HTAU transfected cells. 
Furthermore, transient expression of HTAU in COS-7 
cells did not confer iodide uptake (data not shown), 
suggesting that the enhanced taurine uptake in the 
transfected COS-7 cells did not result from non-specific 
perturbation of the membrane. 
3.4. Taurine uptake in FRTL-5 cells is regulated by TSH 
through CAMP 
It is known that taurine concentration is high in cells 
and tissues that possess considerable potential for pro- 
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ducing oxidants [I]. In the thyroid gland, thyroperoxi- 
dase is highly expressed, and is essential for the produc- 
tion of thyroid hormone. Moreover, the administration 
of thyroid hormone to rats changed the content of tau- 
rine in various tissues [17]. However, to date, neither the 
role of taurine nor its regulation in thyroid gland has 
been studied. Since TSH is essential for the growth and 
function of normal thyroid gland, the taurine uptake 
was investigated in TSH-deprived FRTL-5 cells. Tau- 
rine uptake was downregulated by TSH deprivation in 
FRTL-5 cells. However, the taurine uptake activity in 
TSH deprived cells was restored almost completely by 
treatment with 2 mM CAMP (Fig. 4). Similarly, the 
thyroid-specific iodide uptake has been shown to be 
TSH-dependent, and the TSH-stimulated iodide uptake 
could be mimicked by exogenous CAMP in FRTL-5 
cells [I 11. In the presence of TSH, the addition of CAMP 
did not increase either taurine or iodide uptake (data 
not shown). This indicates that both taurine and iodide 
uptake are regulated by TSH, and largely through 
CAMP as the second messenger. Further study is under- 
way to determine if HTAU is regulated by TSH in the 
thyroid gland. 
3.5. Higher taurine uptake may be associated with higher 
proliferation rate in cultured-cell lines 
The relative taurine uptake activity among several 
cell-lines was determined. The results showed that the 
taurine uptake activities in TPC-1, COS-7, and NPA 
cells are generally higher than in WRO, and TT cells 
(Fig. 5A). Although the cell density has shown some 
effect on the taurine uptake activity within the same 
cells, except TT cells (Fig. 5B, data of COS-7 and NPA 
cells not shown), the cell density does not appear to have 
an effect on the relative taurine uptake activity among 
these cells (Fig. 5B). Interestingly, the proliferation rate 
of TPC-1, COS-7, and NPA cells is higher than that of 
WRO and TT cells (Fig. 5A), suggesting that taurine 
uptake may be associated with proliferation rate. Con- 
sidering the important roles that taurine plays in mem- 
brane stabilization, detoxification, antioxidation, and 
osmoregulation, higher taurine uptake may be essential 
to protect the proliferating cells from self-destruction, 
such as during processes that generate oxidants. In a cell 
culture system where tam-me concentrations can be con- 
trolled, taurine has been shown to enhance the prolifer- 
ation of human lymphoblastoid cells [18] and human 
retinal pigment epithelial cells [19] in a concentration- 
dependent manner. It is noteworthy that, for osmoregu- 
lation, taurine uptake in kidney cells increases signifi- 
cantly under hypertonic conditions with no change of 
cell proliferation [7]. Therefore, taurine uptake may be 
regulated by different factors in different cells. 
3.6. Conclusion 
[16] Snyder, S.H. (1991) Nature 354, 187. 
[17] Nozaki, M. (1989) Rinsho. Shinkeigaku 29, 713-719. 
[18] GaulI, G.E., Wright, C.E. and Tallan, H.H., in: Sulfur Amino 
Acids: Biochemical and Clinical Aspects (K. Kuriyama, R.J. 
Huxtable and H. Iwata, Eds.), Liss, New York, 1983, pp. 297- 
304. 
The primary structure of the human tam-me trans- [19] Gabrielian, K., Wang, H.M., Ogden, T.E. and Ryan, S.J. (1992) 
porter has been determined. Alignment of the human, Curr. Eye Res. 11, 481487. 
dog, and rat taurine transporters howed that the tau- 
rine transporter is highly conserved among these spe- 
cies. This suggests that taurine plays fundamental roles 
in mammals. However, to date, it is not clear how tau- 
rine serves a variety of functions in different tissues. In 
dog kidney cells, taurine uptake is regulated by hyper- 
tonicity [7]. However, in FRTL-5 cells, taurine uptake 
appears to be regulated by TSH through CAMP. Al- 
though taurine has been shown to stimulate prolifera- 
tion in some cells [18,19], this study is the first to dem- 
onstrate that a higher taurine uptake may be associated 
with a higher proliferation rate in cultured cell-lines. 
Finally, cloning of the taurine transporters hould open 
an avenue for the definition of the role of taurine in a 
variety of tissues. 
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